Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine micro-dosing in frontline healthcare workers with acute stress disorder
NCT04769297Phase 4Unknown
- Sponsor
- Limbic
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ketamine in acute stress disorder (ASD), sponsored by Limbic. Primary endpoints: NIH Patient-Reported Outcomes Measurement Information System Computerized Adaptive Test for Stress up to 120 days, NIH Patient-Reported Outcomes Measurement Information System Computerized Adaptive Test for Depression up to 120 days and 2 more. Status: unknown.
02
Drugs
ketamine
03
Conditions
acute stress disorder (ASD)
Beyond the preview
Go deeper on NCT04769297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04769297.